Implementation of pharmacogenetics for treatment of patients with acute lymphoblastic leukemia
Авторы
-
Violeta Graiqevci-Uka
University Clinical Center
https://orcid.org/0000-0002-3653-1407
-
Emir Behluli
University Clinical Center
https://orcid.org/0000-0002-0889-5510
-
Rifat Hadziselimovic
University of Sarajevo
https://orcid.org/0000-0002-6590-8824
-
Thomas Liehr
Jena University Hospital, Friedrich Schiller University
https://orcid.org/0000-0003-1672-3054
-
Gazmend Temaj
College UBT
https://orcid.org/0000-0003-4807-2938
DOI:
https://doi.org/10.18413/rrpharmacology.10.382Аннотация
Introduction: Acute lymphoblastic leukemia (ALL) is the most frequent pediatric leukemia; it can be defined according to chromosomic and genomic data. Cytogenetic analyses and determination of chromosomal numbers (such as hypo- or hyperdiploidy) and/or specific chromosomal rearrangements are basic for ALL classification and treatment. Even though cure rates of childhood ALL are at ~95%, pharmacogenetic aspects are of raising importance.
Material and Methods: We have analyzed the literature for ALL subtypes, corresponding therapy options, and pharmacogenetic implications.
Results: Data for ALL subtypes such as B-ALL, T-ALL, Ph-like ALL, DS-ALL, ETP-ALL, BCR-ABL1-like ALL are presented here. The gene polymorphism which lead to metabolizability of 6-MP are ITPA variants (94C>A) and IVS2+21A>C, in conjunction with TPMT (238G>C, TPMT*3B 460G>A and *3C 719A>G and NUDT15 (415C>T). For methotrexate metabolism gene polymorphisms are found for gene MTHFR as C677T and A1298C.
Conclusion: In the last decade in many hospital laboratories, pharmacogenetic aspects gain more and more importance. Application of many molecular biology methods provided progress in treatment and diagnosis of ALL patients. Combination therapy is proposed as an alternative to single drug treatments.
Графическая аннотация
Ключевые слова:
B-ALL, T-ALL, Ph-Like ALL, methotrexate, 6-mercaptopurineБиблиографические ссылки
Al-Mahayri ZN, Patrinos GP, Ali BR (2017) Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations. Pharmacogenomics 18(7): 687–699. https://doi.org/10.2217/pgs-2017-0005 [PubMed]
Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG (2018) The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature 562(7727): 373–379. https://doi.org/10.1038/s41586-018-0436-0 [PubMed] [PMC]
Behluli E, Nuhii N, Liehr T, Temaj G (2022) Suspicions regarding the genetic inheritance of acute lymphoblastic leukemia in patients with down syndrome. Journal of Mother and Child 26(1): 104–110. https://doi.org/10.34763/jmotherandchild.20222601.d-22-00002 [PubMed] [PMC]
Boer JM, Valsecchi MG, Hormann FM, Antić Ž, Zaliova M, Schwab C, Cazzaniga G, Arfeuille C, Cavé H, Attarbaschi A, Strehl S, Escherich G, Imamura T, Ohki K, Grüber TA, Sutton R, Pastorczak A, Lammens T, Lambert F, Li CK, Carrillo de Santa Pau E, Hoffmann S, Möricke A, Harrison CJ, Den Boer ML, De Lorenzo P, Stam RW, Bergmann AK, Pieters R (2021) Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia 35(10): 2978–2982. https://doi.org/10.1038/s41375-021-01333-y [PubMed] [PMC]
Cao Y, Wang X, Cao Z, Wu C, Wu D, Cheng X (2018) Genetic polymorphisms of MBL2 and tuberculosis susceptibility: A metaanalysis of 22 case-control studies. Archives of Medical Sciences 14(6): 1212–1232. https://doi.org/10.5114/aoms.2017.65319 [PubMed] [PMC]
Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? Journal of Clinical Investigation 76(3): 907–9 https://doi.org/10.1172/JCI112088 [PubMed] [PMC]
Cheng L, Zeng S, Yan D, Tu L, Yang Y, Wang X, Zheng X (2021) Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression. Leukemia Research 109: 106649. https://doi.org/10.1016/j.leukres.2021.106649 [PubMed]
Costa HZ, Pereira NF, Kaminski L, Pasquini R, Funke VAM, Mion ALV (2018) Mutations in the breakpoint cluster region-Abelson murine leukemia 1 gene in Brazilian patients with chronic myeloid leukemia. Hematology, Transfusion and Cell Therapy 40(4): 363–367. https://doi.org/10.1016/j.htct.2018.03.005 [PubMed] [PMC]
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D (2009) Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncology 10(2): 147– https://doi.org/10.1016/S1470-2045(08)70314-0 [PubMed] [PMC]
Davis K, Sheikh T, Aggarwal N (2023) Emerging molecular subtypes and therapies in acute lymphoblastic leukemia. Seminars in Diagnostic Pathology 40(3): 202– https://doi.org/10.1053/j.semdp.2023.04.003 [PubMed]
Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, Van Zutven LJ, Beverloo HB, Van der Spek PJ, Escherich G, Horstmann MA, Janka-Schaub GE, Kamps WA, Evans WE, Pieters R (2009) A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncology 10(2): 125– https://doi.org/10.1016/S1470-2045(08)70339-5 [PubMed] [PMC]
Di Francia R, Crisci S, De Monaco A, Cafiero C, Re A, Iaccarino G, De Filippi R, Frigeri F, Corazzelli G, Micera A, Pinto A (2021) Response and toxicity to cytarabine therapy in leukemia and lymphoma: From dose puzzle to pharmacogenomic biomarkers. Cancers 13(5): 966. https://doi.org/10.3390/cancers13050966 [PubMed] [PMC]
Duffield AS, Mullighan CG, Borowitz MJ (2023) International consensus classification of acute lymphoblastic leukemia/lymphoma. Virchows Archiv 482(1): 11–26. https://doi.org/10.1007/s00428-022-03448-8 [PubMed] [PMC]
Evans WE, Crews KR, Pui CH (2013) A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm. Clinical Pharmacology Therapy 94(2): 224–229. https://doi.org/10.1038/clpt.2013.9 [PubMed] [PMC]
Faderl S, O’Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM (2010) Adult acute lymphoblastic leukemia. Cancer 116(5): 1165–1176. https://doi.org/10.1002/cncr.24862[PubMed] [PMC]
Graiqevci-Uka V, Behluli E, Spahiu L, Liehr T, Temaj G (2023) A new case of childhood acute lymphoblastic B-Cell leukemia from Pristina. Acta Medica Bulgarica 50(1): 59–62. https://doi.org/10.2478/amb-2023-0009
Graiqevci-Uka V, Behluli E, Spahiu L, Liehr T, Temaj G (2023) Targeted treatment and immunotherapy in high-risk and relapsed/refractory pediatric acute lymphoblastic leukemia. Current Pediatric Review 19(12): 150–156. https://doi.org/10.2174/1573396318666220901165247 [PubMed] [PMC]
Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG (2019) PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics 51(2): 296–307. https://doi.org/10.1038/s41588-018-0315-5 [PubMed] [PMC]
Hao QS, Wang Z, Fang QY, Gong XY, Liu KQ, Li Y, Wei H, Wang Y, Li QH, Wang M, Tian Z, Wang JX, Mi YC (2021) Effect of genetic polymorphism of TPMT and NUDT15 on the tolerance of 6-mercaptopurine therapy in adult acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi 42(11): 911–https://doi.org/10.3760/cma.j.issn.0253-2727.2021.11.005[PubMed] [PMC] [in Chinese]
Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: A report from the International BFM Study Group. Blood 115(5): 1006–1017.https://doi.org/10.1182/blood-2009-08-235408 [PubMed]
Hetzel S, Mattei AL, Kretzmer H, Qu C, Chen X, Fan Y, Wu G, Roberts KG, Luger S, Litzow M, Rowe J, Paietta E, Stock W, Mardis ER, Wilson RK, Downing JR, Mullighan CG, Meissner A (2022) Acute lymphoblastic leukemia displays a distinct highly methylated genome. Nature Cancer 3(6): 768–https://doi.org/10.1038/s43018-022-00370-5 [PubMed] [PMC]
Hirabayashi S, Butler ER, Ohki K, Kiyokawa N, Bergmann AK, Möricke A, Boer JM, Cavé H, Cazzaniga G, Yeoh AEJ, Sanada M, Imamura T, Inaba H, Mullighan C, Loh ML, Norén-Nyström U, Pastorczak A, Shih LY, Zaliova M, Pui CH, Haas OA, Harrison CJ, Moorman AV, Manabe A (2021) Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: A retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Leukemia 35(11): 3272–3277. https://doi.org/10.1038/s41375-021-01199-0 [PubMed] [PMC]
Hoelzer D, Bassan R, Dombret H, Ribera J, Buske C (2016) Acute lymphoblastic leukemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Hematology and Oncology 27(suppl 5): 69–82.https://doi.org/10.1093/annonc/mdw025 [PubMed]
Hoppmann AL, Chen Y, Landier W, Hageman L, Evans WE, Wong FL, Relling MV, Bhatia S (2021) Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1. Cancer 127(20): 3832–https://doi.org/10.1002/cncr.33760 [PubMed] [PMC]
Hormann FM, Hoogkamer AQ, Beverloo HB, Boeree A, Dingjan I, Wattel MM, Stam RW, Escherich G, Pieters R, den Boer ML, Boer JM (2019) NUTM1 is a recurrent fusion gene partner in B-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2. Haematologica 104(10): e455–e459. https://doi.org/10.3324/haematol.2018.206961 [PubMed] [PMC]
Hu G, Cheng Y, Zuo Y, Chang Y, Suo P, Jia Y, Lu A, Wang Y, Jiao S, Zhang L, Sun Y, Yan C, Xu L, Zhang X, Liu K, Wang Y, Zhang L, Huang X (2022) Comparisons of long-term survival and safety of haploidentical hematopoietic stem cell transplantation after CAR-T cell therapy or chemotherapy in pediatric patients with first relapse of B-cell acute lymphoblastic leukemiabased on MRD-guided t Frontiers in Immunology 13: 915590.https://doi.org/10.3389/fimmu.2022.915590 [PubMed] [PMC]
Hunger SP (1996) Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: Clinical features and molecular pathogenesis. Blood 87(4): 1211– [PubMed]
Hunger SP, Raetz EA (2020) How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood 136(16): 1803–https://doi.org/10.1182/blood.2019004043[PubMed]
Iacobucci I, Kimura S, Mullighan CG (2021) Biologic and therapeutic implications ofgenomicalterations in acute lymphoblasticleukemia. Journal of Clinical Medicine 10(17): 3792. https://doi.org/10.3390/jcm10173792 [PubMed] [PMC]
Iacobucci I, Li Y, Roberts KG, Dobson SM, Kim JC, Payne-Turner D, Harvey RC, Valentine M, McCastlain K, Easton J, Yergeau D, Janke LJ, Shao Y, Chen IM, Rusch M, Zandi S, Kornblau SM, Konopleva M, Jabbour E, Paietta EM, Rowe JM, Pui CH, Gastier-Foster J, Gu Z, Reshmi S, Loh ML, Racevskis J, Tallman MS, Wiernik PH, Litzow MR, Willman CL, McPherson JD, Downing JR, Zhang J, Dick JE, Hunger SP, Mullighan CG (2016) Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. Cancer Cell 29(2): 186–200. https://doi.org/10.1016/j.ccell.2015.12.013 [PubMed] [PMC]
Iacobucci I, Mullighan CG (2017) Genetic basis of acute lymphoblastic leukemia. Journal of Clinical Oncology 35(9): 975–983. https://doi.org/10.1200/JCO.2016.70.7836 [PubMed] [PMC]
Izraeli S, Vora A, Zwaan CM, Whitlock J (2014) How I treat All in Down's syndrome: Pathobiology and management. Blood 123(1): 35– https://doi.org/10.1182/blood-2013-07-453480 [PubMed]
Jackson RK, Irving JA, Veal GJ (2016) Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia. British Journal of Hematology 173(1): 13–https://doi.org/10.1111/bjh.13924 [PubMed]
Jackson RK, Liebich M, Berry P, Errington J, Liu J, Parker C, Moppett J, Samarasinghe S, Hough R, Rowntree C, Goulden NJ, Vora A, Kearns PR, Saha V, Hempel G, Irving JAE, Veal GJ (2019) Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia: A report from the UKALL 2011 trial. European Journal of Cancer 120: 75–https://doi.org/10.1016/j.ejca.2019.07.026 [PubMed]
Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD (2016) Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: A high-risk subtype. Blood 127(15): 1863–1869. https://doi.org/10.1182/blood-2015-08-661702 [PubMed] [PMC]
Kandikonda P, Bostrom B (2019) Methotrexate polyglutamate values in children and adolescents with acute lymphoblastic leukemia during maintenance therapy. Journal of Pediatric Hematology/Oncology 41(6): 429–https://doi.org/10.1097/MPH.0000000000001530 [PubMed]
Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, Howard SC, Campana D, Panetta JC, Bowman WP, Evans WE, Pui CH, Relling MV (2012) Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 119(7): 1658–1664. https://doi.org/10.1182/blood-2011-09-381731 [PubMed] [PMC]
Kimura S, Mullighan CG (2020) Molecular markers in ALL: Clinical implications. Best Practice & Research Clinical Haematology 33(3): 101193. https://doi.org/10.1016/j.beha.2020.101193 [PubMed] [PMC]
Krajinovic M, Costea I, Chiasson S (2002) Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 359(9311): 1033–https://doi.org/10.1016/S0140-6736(02)08065-0 [PubMed]
Künz T, Hauswirth AW, Hetzenauer G, Rudzki J, Nachbaur D, Steiner N (2022) Changing landscape in the treatment of adult acute lymphoblastic leukemia (ALL). Cancers 14(17): 4290. https://doi.org/10.3390/cancers14174290 [PubMed] [PMC]
Lamba JK (2009) Genetic factors influencing cytarabine therapy. Pharmacogenomics 10(10): 1657–1674. https://doi.org/10.2217/pgs.09.118 [PubMed] [PMC]
Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R (2007) Pharmacogenetics of deoxycytidine kinase: Identification and characterization of novel genetic variants. Journal of Pharmacological and Experimental Therapy 323(3): 935–945. https://doi.org/10.1124/jpet.107.128595 [PubMed]
Larsen RH, Hjalgrim LL, Grell K, Kristensen K, Pedersen LG, Brünner ED, Als-Nielsen B, Schmiegelow K, Nersting J (2020) Pharmacokinetics of tablet and liquid formulations of oral 6 ‑mercaptopurine in children with acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology 86(1): 25–https://doi.org/10.1007/s00280-020-04097-x [PubMed]
Lee SHR, Yang JJ (2017) Pharmacogenomics in acute lymphoblastic leukemia. Best Practice & Research Clinical Haematology 3(3): 229–236. https://doi.org/10.1016/j.beha.2017.07.007[PubMed]
Li J, Dai Y, Wu L, Zhang M, Ouyang W, Huang J, Chen S (2021) Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia. Frontiers in Medicine 15(3): 347–371. https://doi.org/10.1007/s11684-020-0821-6 [PubMed]
Li JF, Dai YT, Lilljebjörn H, Shen SH, Cui BW, Bai L, Liu YF, Qian MX, Kubota Y, Kiyoi H, Matsumura I, Miyazaki Y, Olsson L, Tan AM, Ariffin H, Chen J, Takita J, Yasuda T, Mano H, Johansson B, Yang JJ, Yeoh AE, Hayakawa F, Chen Z, Pui CH, Fioretos T, Chen SJ, Huang JY (2018) Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1223 cases. Proceedings of the National Academy of Sciences of the United States of America 115(50): E11711–E11720. https://doi.org/10.1073/pnas.1814397115 [PubMed] [PMC]
Li Y, Schwab C, Ryan S, Papaemmanuil E, Robinson HM, Jacobs P, Moorman AV, Dyer S, Borrow J, Griffiths M, Heerema NA, Carroll AJ, Talley P, Bown N, Telford N, Ross FM, Gaunt L, McNally RJQ, Young BD, Sinclair P, Rand V, Teixeira MR, Joseph O, Robinson B, Maddison M, Dastugue N, Vandenberghe P, Stephens PJ, Cheng J, Van Loo P, Stratton MR, Campbell PJ, Harrison CJ (2014) Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 508(7494): 98– https://doi.org/10.1038/nature13115[PubMed] [PMC]
Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, McCastlain K, Edmonson M, Pounds SB, Shi L, Zhou X, Ma X, Sioson E, Li Y, Rusch M, Gupta P, Pei D, Cheng C, Smith MA, Auvil JG, Gerhard DS, Relling MV, Winick NJ, Carroll AJ, Heerema NA, Raetz E, Devidas M, Willman CL, Harvey RC, Carroll WL, Dunsmore KP, Winter SS, Wood BL, Sorrentino BP, Downing JR, Loh ML, Hunger SP, Zhang J, Mullighan CG (2017) The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nature Genetics 49(8): 1211–1218. https://doi.org/10.1038/ng.3909 [PubMed] [PMC]
Liu YF, Wang BY, Zhang WN, Huang JY, Li BS, Zhang M, Jiang L, Li JF, Wang MJ, Dai YJ, Zhang ZG, Wang Q, Kong J, Chen B, Zhu YM, Weng XQ, Shen ZX, Li JM, Wang J, Yan XJ, Li Y, Liang YM, Liu L, Chen XQ, Zhang WG, Yan JS, Hu JD, Shen SH, Chen J, Gu LJ, Pei D, Li Y, Wu G, Zhou X, Ren RB, Cheng C, Yang JJ, Wang KK, Wang SY, Zhang J, Mi JQ, Pui CH, Tang JY, Chen Z, Chen SJ (2016) Genomic profiling of adult and pediatric b-cell acute lymphoblastic leukemia. EBioMedicine 8: 173–183. https://doi.org/10.1016/j.ebiom.2016.04.038 [PubMed] [PMC]
Lopez-Lopez E, Gutierrez-Camino A, Bilbao-Aldaiturriaga N, Pombar- Gomez M, Martin-Guerrero I, Garcia-Orad A (2014) Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics 15(10): 1383–1398. https://doi.org/10.2217/pgs.14.106[PubMed]
Lu S, Zhu X, Li W, Chen H, Zhou D, Zhen Z, Sun F, Huang J, Zhu J, Wang J, Zhang Y, Sun X(2021) Influence of methylenetetrahydrofolate reductase C677T and A1298C polymorphism on high-dose methotrexate-related toxicities in pediatric non-Hodgkin lymphoma patients. Frontiers in Oncology 11: 598226. https://doi.org/10.3389/fonc.2021.598226 [PubMed] [PMC]
Lv M, Zhuang X, Shao S, Li X, Cheng Y, Wu D, Wang X, Qiao T (2022) Immunotherapy for pediatric acute lymphoblastic leukemia: Recent advances and future perspectives. Journal of Immunology Research 13: 921894. https://doi.org/10.3389/fimmu.2022.921894 [PubMed] [PMC]
Mao X, Yin R, Sun G, Zhou Y, Yang C, Fang C, Wu Y, Cui T, Liu L, Gan J, Tian X (2021) Effects of TPMT, NUDT15, and ITPA genetic variants on 6-mercaptopurine toxicity for pediatric patients with acute lymphoblastic leukemia in Yunnan of China. Frontiers in Pediatrics 9: 719803. https://doi.org/10.3389/fped.2021.719803 [PubMed] [PMC]
McEvoy CR, Fox SB, Prall OWJ (2020) Emerging entities in NUTM1-rearranged neoplasms. Genes, Chromosomes and Cancer 59(6): 375–385. https://doi.org/10.1002/gcc.22838[PubMed]
Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, Wetzler M (2015) Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Review 29(4): 243–249. https://doi.org/10.1016/j.blre.2015.01.001 [PubMed] [PMC]
Mendoza-Santiago A, Becerra E, Garay E, Bah M, Berumen-Segura L, Escobar-Cabrera J, Hernández-Pérez A, García-Alcocer G (2019) Glutamic acid increased methotrexate polyglutamation and cytotoxicity in a CCRF-SB acute lymphoblastic leukemia cell line. Medicina (Kaunas) 55(12): 758. https://doi.org/10.3390/medicina55120758 [PubMed] [PMC]
Montefiori LE, Bendig S, Gu Z, Chen X, Pölönen P, Ma X, Murison A, Zeng A, Garcia-Prat L, Dickerson K, Iacobucci I, Abdelhamed S, Hiltenbrand R, Mead PE, Mehr CM, Xu B, Cheng Z, Chang TC, Westover T, Ma J, Stengel A, Kimura S, Qu C, Valentine MB, Rashkovan M, Luger S, Litzow MR, Rowe JM, den Boer ML, Wang V, Yin J, Kornblau SM, Hunger SP, Loh ML, Pui CH, Yang W, Crews KR, Roberts KG, Yang JJ, Relling MV, Evans WE, Stock W, Paietta EM, Ferrando AA, Zhang J, Kern W, Haferlach T, Wu G, Dick JE, Klco JM, Haferlach C, Mullighan CG (2021) Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia. Cancer Discover 11(11): 2846–2867. https://doi.org/10.1158/2159-8290.CD-21-0145 [PubMed] [PMC]
Moorman AV, Barretta E, Butler ER, Ward EJ, Twentyman K, Kirkwood AA, Enshaei A, Schwab C, Creasey T, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Marks DI, Fielding AK (2022) Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: A UKALL14 study. Leukemia 36(3): 625–636.https://doi.org/10.1038/s41375-021-01448-2 [PubMed] [PMC]
Moradveisi B, Muwakkit S, Zamani F, Ghaderi E, Mohammadi E, Zgheib NK (2019) ITPA, TPMT, and NUDT15 genetic polymorphisms predict 6-mercaptopurine toxicity in Middle Eastern children with acute lymphoblastic leukemia. Frontiers in Pharmacology 10: 916. https://doi.org/10.3389/fphar.2019.00916 [PubMed] [PMC]
Mullighan CG (2019) How advanced are we in targeting novel subtypes of ALL? Best Practice & Research Clinical Haematology 32(4): 101095. https://doi.org/10.1016/j.beha.2019.101095 [PubMed] [PMC]
Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Willman CL, Mikhail FM, Meyer J, Carroll AJ, Williams RT, Cheng J, Heerema NA, Basso G, Pession A, Pui CH, Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin KR (2009) Rearrangement of CRLF2 in B-progenitor–and Down syndrome–associated acute lymphoblastic leukemia. Nature Genetics 41(11): 1243–1246. https://doi.org/10.1038/ng.469 [PubMed] [PMC]
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, Harvey RC, Chen IM, Clifford RJ, Carroll WL, Reaman G, Bowman WP, Devidas M, Gerhard DS, Yang W, Relling MV, Shurtleff SA, Campana D, Borowitz MJ, Pui CH, Smith M, Hunger SP, Willman CL, Downing JR; Children’s Oncology Group (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. The New England Journal of Medicine 360(5): 470– https://doi.org/10.1056/NEJMoa0808253 [PubMed] [PMC]
Nakano T, Kobayashi R, Matsushima S, Hori D, Yanagi M, Suzuki D, Kobayashi K (2021) Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma. International Journal of Hematology 113(5): 744–https://doi.org/10.1007/s12185-020-03071-w [PubMed]
Nersting J, Nielsen SN, Grell K, Paerregaard M, Abrahamsson J, Lund B, Jonsson OG, Pruunsild K, Vaitkeviciene G, Kanerva J, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO) (2019) Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy. Cancer Chemotherapy and Pharmacology 83(1): 53– https://doi.org/10.1007/s00280-018-3704-7 [PubMed]
Paganin M, Ferrando A (2011) Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Reviews 25(2): 83–https://doi.org/10.1016/j.blre.2010.09.004 [PubMed] [PMC]
Pai AA, Young-Sing Q, Bera S, Maheshwari K, Misra A (2022) Analysis of clinical and patient-reported outcomes in post-ELAPE perineal reconstruction with IGAP flap - A 5-year review. JPRAS Open 34:10–https://doi.org/10.1016/j.jpra.2022.06.002 [PubMed] [PMC]
Paietta E, Roberts KG, Wang V, Gu Z, Buck GAN, Pei D, Cheng C, Levine RL, Abdel-Wahab O, Cheng Z, Wu G, Qu C, Shi L, Pounds S, Willman CL, Harvey R, Racevskis J, Barinka J, Zhang Y, Dewald GW, Ketterling RP, Alejos D, Lazarus HM, Luger SM, Foroni L, Patel B, Fielding AK, Melnick A, Marks DI, Moorman AV, Wiernik PH, Rowe JM, Tallman MS, Goldstone AH, Mullighan CG, Litzow MR (2021) Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood Advances 138(11): 948–958.https://doi.org/10.1182/blood.2020010144 [PubMed] [PMC]
Parker H, An Q, Barber K, Case M, Davies T, Konn Z, Stewart A, Wright S, Griffiths M, Ross FM, Moorman AV, Hall AG, Irving JA, Harrison CJ, Strefford JC (2008) The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes Chromosomes Cancer 47(12): 1118–https://doi.org/10.1002/gcc.20613 [PubMed]
Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Cheng IM, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, Dean M, Burchard EG, Torgerson DG, Yue F, Wang Y, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ (2015) A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 125(4): 680–https://doi.org/10.1182/blood-2014-09-595744 [PubMed] [PMC]
Perez-Andreu V, Xu H, Yang JJ (2013) The novel susceptibility variants for childhood acute lymphoblastic leukemia. Journal of the National Cancer Institute 105(19): 1512–https://doi.org/10.1093/jnci/djt230 [PubMed] [PMC]
Phillips NS, Cheung YT, Glass JO, Scoggins MA, Liu W, Ogg RJ, Mulrooney DA, Pui CH, Robison LL, Reddick WE, Hudson MM, Krull KR (2020) Neuroanatomical abnormalities related to dexamethasone exposure in survivors of childhood acute lymphoblastic leukemia. Pediatric Blood & Cancer 3: e27968. https://doi.org/10.1002/pbc.27968 [PubMed] [PMC]
Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG (2007) A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 370(9583): 240–https://doi.org/10.1016/S0140-6736(07)61126-X [PubMed]
Pui CH (2015) Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia. Frontiers of Medicine 9: 1– https://doi.org/10.1007/s11684-015-0381-3[PubMed]
Pui CH, Nichols KE, Yang JJ (2018) Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nature Reviews Clinical Oncology 16(4): 227–240. https://doi.org/10.1038/s41571-018-0136-6 [PubMed]
Raimondi SC, Behm FG, Roberson PK, Williams DL, Pui CH, Crist WM, Look AT, Rivera GK (1990) Cytogenetics of pre-B-cell acute lymphoblastic leukemia with emphasis on prognostic implications of the t(1;19). Journal of Clinical Oncology 8: 1380–https://doi.org/10.1200/JCO.1990.8.8.1380 [PubMed]
Roberts KG (2017) The biology of Philadelphia chromosome-like ALL. Best Practice & Research Clinical Haematology 30(3): 212–221. https://doi.org/10.1016/j.beha.2017.07.003[PubMed]
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. The New England Journal of Medicine 371(11): 1005–1015. https://doi.org/10.1056/NEJMoa1403088 [PubMed] [PMC]
Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, Mungall K, Birol I, Edmonson MN, Hu Y, Buetow KE, Chen IM, Carroll WL, Wei L, Ma J, Kleppe M, Levine RL, Garcia-Manero G, Larsen E, Shah NP, Devidas M, Reaman G, Smith M, Paugh SW, Evans WE, Grupp SA, Jeha S, Pui CH, Gerhard DS, Downing JR, Willman CL, Loh M, Hunger SP, Marra MA, Mullighan CG (2012) Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22(2): 153–166. https://doi.org/10.1016/j.ccr.2012.06.005 [PubMed] [PMC]
Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C, Sandlund JT, Jeha S, Easton J, Becksfort J, Zhang J, Coustan-Smith E, Raimondi SC, Leung WH, Relling MV, Evans WE, Downing JR, Mullighan CG, Pui CH (2014) Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. Journal of Clinical Oncology 32(27): 3012–https://doi.org/10.1200/JCO.2014.55.4105 [PubMed] [PMC]
Rosen G, Harris AK, Liu M, Dreyfus J, Krueger J, Messinger YH (2015) The effects of dexamethasone on sleep in young children with acute lymphoblastic leukemia. Sleep Medicine 16(4): 503–50https://doi.org/10.1016/j.sleep.2014.11.002 [PubMed] [PMC]
Rudin S, Marable M, Huang RS (2017) The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment. Genomics Proteomics Bioinformatics 15(2): 82–93. https://doi.org/10.1016/j.gpb.2016.11.003 [PubMed] [PMC]
Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, Chandrasekaran T, Chapiro E, Gesk S, Griffiths M, Guttery DS, Haferlach C, Harder L, Heidenreich O, Irving J, Kearney L, Nguyen-Khac F, Machado L, Minto L, Majid A, Moorman AV, Morrison H, Rand V, Strefford JC, Schwab C, Tönnies H, Dyer MJ, Siebert R, Harrison CJ (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114(13): 2688–https://doi.org/10.1182/blood-2009-03-208397 [PubMed]
Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, Nakjang S, Papaemmanuil E, Tubio JM, Fielding AK, Vora A, Campbell PJ, Moorman AV, Harrison CJ (2017) Characterisation of the genomic landscape ofCRLF2-rearranged acute lymphoblastic leukemia. Genes, Chromosomes and Cancer 56(5): 363–372. https://doi.org/10.1002/gcc.22439 [PubMed] [PMC]
Schmiegelow K (2009) Advances in individual prediction of methotrexate toxicity: A review. British Journal of Hematology 146(5): 489– https://doi.org/10.1111/j.1365-2141.2009.07765.x [PubMed]
Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J (2014) Mercaptopurine/ Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: Clinical facts and fiction. Journal of Pediatric Hematology/Oncology 36(7): 503–517. https://doi.org/10.1097/MPH.0000000000000206 [PubMed] [PMC]
Schwab C, Harrison CJ (2018) Advances in B-cell precursor acute lymphoblastic leukemia genomics. HemaSphere 2(4): e53. https://doi.org/10.1097/HS9.0000000000000053[PubMed] [PMC]
Seki M, Kimura S, Isobe T, Yoshida K, Ueno H, Nakajima-Takagi Y, Wang C, Lin L, Kon A, Suzuki H, Shiozawa Y, Kataoka K, Fujii Y, Shiraishi Y, Chiba K, Tanaka H, Shimamura T, Masuda K, Kawamoto H, Ohki K, Kato M, Arakawa Y, Koh K, Hanada R, Moritake H, Akiyama M, Kobayashi R, Deguchi T, Hashii Y, Imamura T, Sato A, Kiyokawa N, Oka A, Hayashi Y, Takagi M, Manabe A, Ohara A, Horibe K, Sanada M, Iwama A, Mano H, Miyano S, Ogawa S, Takita J (2017) Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nature Genetics 49(8): 1274–1281. https://doi.org/10.1038/ng.3900 [PubMed]
Shen Y, Wang Z, Zhou F, Jin R (2021) The influence of MTHFR genetic polymorphisms on methotrexate therapy in pediatric acute lymphoblastic leukemia. Open Life Science 16(1): 1203–https://doi.org/10.1515/biol-2021-0121 [PubMed] [PMC]
Sin CF, Man PM (2021) Early T-Cell precursor acute lymphoblastic leukemia: Diagnosis, updates in molecular pathogenesis, management, and novel therapies. Frontiers in Oncology 11: 750789. https://doi.org/10.3389/fonc.2021.750789 [PubMed] [PMC]
Stanulla M, Schrappe M, Yang SK (2009) Treatment of childhood acute lymphoblastic leukemia. Seminar Hematology 46(1): 52–63. https://doi.org/10.1053/j.seminhematol.2008.09.007 [PubMed]
Tanasi I, Ba I, Sirvent N, Braun T, Cuccuini W, Ballerini P, Duployez N, Tanguy-Schmidt A, Tamburini J, Maury S, Doré E, Himberlin C, Duclos C, Chevallier P, Rousselot P, Bonifacio M, Cavé H, Baruchel A, Dombret H, Soulier J, Landman-Parker J, Boissel N, Clappier E (2019) Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.Blood 134(16): 1351–1355. https://doi.org/10.1182/blood.2019001244 [PubMed]
Tarantini F, Cumbo C, Anelli L, Zagaria A, Specchia G, Musto P, Albano F (2021) Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick. Biomark Research 9(1): 89. https://doi.org/10.1186/s40364-021-00347-z [PubMed] [PMC]
Tasian SK, Loh ML, Hunger SP (2015) Childhood acute lymphoblastic leukemia: Integrating genomics into therapy. Cancer 121(20): 3577– https://doi.org/10.1002/cncr.29573[PubMed] [PMC]
Tolbert JA, Bai S, Abdel-Rahman SM, August KJ, Weir SJ, Kearns GL, Neville KA (2017) Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer 8: https://doi.org/10.1002/pbc.26465[PubMed]
Ueno H, Yoshida K, Shiozawa Y, Nannya Y, Iijima-Yamashita Y, Kiyokawa N, Shiraishi Y, Chiba K, Tanaka H, Isobe T, Seki M, Kimura S, Makishima H, Nakagawa MM, Kakiuchi N, Kataoka K, Yoshizato T, Nishijima D, Deguchi T, Ohki K, Sato A, Takahashi H, Hashii Y, Tokimasa S, Hara J, Kosaka Y, Kato K, Inukai T, Takita J, Imamura T, Miyano S, Manabe A, Horibe K, Ogawa S, Sanada M (2020) Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Advances 4(20): 5165–5173. https://doi.org/10.1182/bloodadvances.2019001307 [PubMed] [PMC]
Umerez M, Gutierrez-Camino Á, Muñoz-Maldonado C, Martin-Guerrero I, Garcia-Orad A (2017) MTHFR polymorphisms in childhood acute lymphoblastic leukemia: Influence on methotrexate therapy. Pharmgenomics and Personalized Medicine 10: 69-78. https://doi.org/10.2147/PGPM.S107047 [PubMed] [PMC]
Van Vlierberghe P, Palomero T, Khiabanian H, Van der Meulen J, Castillo M, Van Roy N, De Moerloose B, Philippé J, González-García S, Toribio ML, Taghon T, Zuurbier L, Cauwelier B, Harrison CJ, Schwab C, Pisecker M, Strehl S, Langerak AW, Gecz J, Sonneveld E, Pieters R, Paietta E, Rowe JM, Wiernik PH, Benoit Y, Soulier J, Poppe B, Yao X, Cordon-Cardo C, Meijerink J, Rabadan R, Speleman F, Ferrando A (2010) PHF6 mutations in T-cell acute lymphoblastic leukemia. Nature Genetics 42(4): 338– https://doi.org/10.1038/ng.542[PubMed] [PMC]
Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R, Rowntree C, Richards S (2013) Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial. Lancet Oncology 14(3): 199– https://doi.org/10.1016/S1470-2045(12)70600-9[PubMed]
Wang DS, Yu CH, Lin CY, Chang YH, Lin KH, Lin DT, Jou ST, Lu MY, Chang HH, Lin SW, Chen HY, Yang YL (2021) Childhood acute lymphoblastic leukemia mercaptopurine intolerance is associated with NUDT15 variants. Pediatric Research 89(1): 217–https://doi.org/10.1038/s41390-020-0868-8 [PubMed]
Wiley JS, Jones SP, Sawyer WH, Paterson AR (1982) Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. Journal of Clinical Investigation 69(2): 479– https://doi.org/10.1172/jci110472 [PubMed] [PMC]
Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP (2015) Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: children’s oncology group study AALL0434. Pediatric Blood & Cancer 62(7): 1176– https://doi.org/10.1002/pbc.25470 [PubMed] [PMC]
Wu C, Li W (2018) Genomics and pharmacogenomics of pediatric acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology 126: 100–https://doi.org/10.1016/j.critrevonc.2018.04.002 [PubMed]
Yang W, Cai J, Shen S, Gao J, Yu J, Hu S, Jiang H, Fang Y, Liang C, Ju X, Wu X, Zhai X, Tian X, Wang N, Liu A, Jiang H, Jin R, Sun L, Yang M, Leung AWK, Pan K, Zhang Y, Chen J, Zhu Y, Zhang H, Li C, Yang JJ, Cheng C, Li CK, Tang J, Zhu X, Pui CH (2021) Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology 22(9): 1322–https://doi.org/10.1016/S1470-2045(21)00328-4 [PubMed] [PMC]
Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H (2016) Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nature Genetics 48(5): 569–574. https://doi.org/10.1038/ng.3535 [PubMed]
Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM (2009) Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 107(1): 252–257. https://doi.org/10.1073/pnas.0911726107 [PubMed] [PMC]
Zaliova M, Stuchly J, Winkowska L, Musilova A, Fiser K, Slamova M, Starkova J, Vaskova M, Hrusak O, Sramkova L, Stary J, Zuna J, Trka J (2019) Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort. Haematologica 104(7): 1396–1406. https://doi.org/10.3324/haematol.2018.204974 [PubMed] [PMC]
Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M, Buetow KH, Carroll WL, Chen IM, Devidas M, Gerhard DS, Loh ML, Reaman GH, Relling MV, Camitta BM, Bowman WP, Smith MA, Willman CL, Downing JR, Hunger SP (2011) Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Blood 118(11): 3080– https://doi.org/10.1182/blood-2011-03-341412[PubMed] [PMC]
Zhou Y, Wang L, Zhai XY, Wen L, Tang F, Yang F, Liu XT, Dong L, Zhi LJ, Shi HY, Hao GX, Zheng Y, Jacqz-Aigrain E, Wang TY, Zhao W (2020) Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia. British Journal of Clinical Pharmacology 86(8): 1519–https://doi.org/10.1111/bcp.14258 [PubMed] [PMC]
Zhu KW, Chen P, Zhang DY, Yan H, Liu H, Cen LN, Liu YL, Cao S, Zhou G, Zeng H, Chen SP, Zhao XL, Chen XP (2018) Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML). Journal of Translational Medicine 16(1): 90. https://doi.org/10.1186/s12967-018-1463-1 [PubMed] [PMC]
Zou Y, Mei D, Yuan J, Han J, Xu J, Sun N, He H, Yang C, Zhao L (2021) Preparation, characterization, pharmacokinetic, and therapeutic potential of novel 6-mercaptopurine-loaded oral nanomedicines for acute lymphoblastic leukemia. International Journal of Nanomedicine 16: 1127–https://doi.org/10.2147/IJN.S290466 [PubMed] [PMC]
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2024 Emir Behluli, Rifat Hadziselimovic, Thomas Liehr, Gazmend Temaj
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Русский
English
